[Skip to Content]
[Skip to Content Landing]
Citations 0
From the Food and Drug Administration
May 1, 2002

Treatment for Liver Tumors

Author Affiliations

Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002American Medical Association

JAMA. 2002;287(17):2203. doi:10.1001/jama.287.17.2203

The FDA has approved SIR-Spheres (Sirtex Medical Inc, New South Wales, Australia) for the treatment of unresectable metastatic liver tumors from primary colorectal cancer together with intrahepatic artery chemotherapy with floxuridine.

The approved device consists of biocompatible microspheres containing yttrium-90 of 20 to 40 µm in diameter. It is implanted into a hepatic tumor by injection into either the common hepatic artery or the right or left hepatic artery via a chemotherapy catheter port. SIR-Spheres distribute unevenly in the liver, and its density in the tumor can be as much as five or six times that in normal liver tissue. The product remains permanently in the liver.

First Page Preview View Large
First page PDF preview
First page PDF preview